Boehringer Pays $95M To Settle FCA Suit Over Drug Marketing

Law360, New York (October 25, 2012, 6:06 PM EDT) -- Boehringer Ingelheim Pharmaceuticals Inc. will pay $95 million to settle a former employee's False Claims Act suit accusing the company of off-label marketing and kickbacks related to stroke-prevention drug Aggrenox and three other drugs, the U.S. Department of Justice announced Thursday.

The settlement, filed in Maryland federal court, resolves claims that Boehringer promoted Aggrenox, chronic obstructive pulmonary disease drugs Combivent and Atrovent, and hypertension drug Micardis to doctors for off-label use between 2000 and 2008, according to the DOJ. It also resolves claims the company paid...
To view the full article, register now.